ScreenerHero

LNAI Lunai Bioworks Inc.

NAS · US · Healthcare · Biotechnology · lunaibioworks.com
1.090USD-3.54%Mkt Cap: 4.94M $P/E: —

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.94M USD
Enterprise Value3.47M USD
Revenue (TTM)20.94K USD
Gross Profit20.94K USD
Net Income (TTM)-178.01M USD
Revenue/Share0.0080 USD
Last Price1.090 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.35
EV/Revenue165.70
P/S244.64
P/B-0.53
EPS (TTM)-60.82
EPS (Forward)—
52W Range
1.0800% of range13.28
52W High13.28 USD
52W Low1.080 USD
Profitability
Gross Margin100.00%
Oper. Margin-6815.30%
EBITDA Margin0.00%
Profit Margin0.00%
ROE833.76%
ROA-2162.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.87M USD
CapEx (TTM)—
FCF Margin-33254.71%
FCF Yield-140.92%
Net Debt-1.74M USD
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity-0.48
Current Ratio0.19
Quick Ratio0.16
Book Value/Sh-2.14 USD
Cash/Share0.70 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateMay 22, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.53M
Float2.87M
Insiders40.72%
Institutions4.36%
Short Interest
Short Ratio4.1d
Short % Float3.38%
Short % Out.2.95%
Shares Short133.72K
Short (prev mo.)155.99K
Technical
SMA 502.180 (-50.0%)
SMA 2003.540 (-69.2%)
Beta0.35
S&P 52W Chg16.45%
Avg Vol (30d)46.72K
Avg Vol (10d)76.65K
Technical Indicators
RSI (14)20.4
MACD-0.3209
MACD Signal-0.2230
MACD Hist.-0.0979
BB Upper2.929 USD
BB Middle1.920 USD
BB Lower0.9109 USD
BB Width105.10%
ATR (14)0.2356 USD
Vol Ratio (20d)0.38x